Vitalhub (VHI) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 Aug, 2026Executive summary
Achieved annual recurring revenue (ARR) of CAD 101.5 million, up 10% organically and 28% year-over-year, with total revenue for Q2 2026 at CAD 31.7 million, a 33% increase year-over-year.
Adjusted EBITDA margin improved to 26%, with adjusted EBITDA at CAD 8.2 million, up 29% year-over-year.
Strong cash position with CAD 136.5 million and no debt at quarter-end.
Completed the acquisition of Buddy Healthcare, expanding digital care offerings and European/Nordic presence.
Integration of major 2025 acquisitions nearly complete, supporting improved earnings quality and scalability.
Financial highlights
Recurring revenue was CAD 24.5 million, representing 77% of total revenue.
Virtual care term license revenue was CAD 2.3 million; perpetual license revenue was CAD 800,000.
Services, hardware, and other revenue reached CAD 4.1 million, up from CAD 2.7 million year-over-year.
Gross margin was 79%, slightly down from 81% in the prior year.
Net income before taxes for Q2 2026 was CAD 3.6 million, up 62% year-over-year; net income after tax was CAD 1.95 million, up 10%.
Outlook and guidance
Organic ARR growth expected to remain in the 10%-11% range, with potential upside depending on U.K. contract uncertainties.
Pro forma ARR post-Buddy Healthcare acquisition is approximately CAD 106 million, positioning for further international scaling.
Continued focus on integrating acquisitions, cross-selling, and expanding AI-driven solutions.
M&A remains a priority, with significant cash reserves available for future deals.
Management emphasizes continued focus on organic growth and M&A to drive future performance.
Latest events from Vitalhub
- ARR up 59% to CAD 71.1m, record Q4 revenue, strong cash, and continued M&A focus.VHI
Q4 20249 Jul 2026 - ARR and revenue surged in 2025, with strong EBITDA margin and cash for acquisitions.VHI
Q4 20251 Jul 2026 - Q2 revenue up 24% YoY, ARR up 25%, and adjusted EBITDA margin reached 26% on strong recurring growth.VHI
Q2 202430 Jun 2026 - Q3 revenue and ARR up 25%, pro forma ARR hits CAD 68M after acquisitions, cash at CAD 81.4M.VHI
Q3 202411 May 2026 - ARR up 54% and revenue up 42%, with CAD 91.2M cash fueling strong M&A activity.VHI
Q1 202511 May 2026 - ARR and revenue surged year-over-year, margins improved, and cash reserves strengthened.VHI
Q1 202611 May 2026 - Growth through acquisitions and AI integration aims to boost recurring revenue and margins by 2026.VHI
2nd Annual Lytham Partners Healthcare Investor Summit15 Jan 2026 - Delivers $93.7M ARR and 22% EBITDA margin through global healthcare software and M&A.VHI
Investor presentation15 Jan 2026 - Healthcare IT firm achieves $70M+ ARR via acquisitions, organic growth, and high-margin solutions.VHI
Planet MicroCap Showcase: VEGAS 202527 Dec 2025